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Abstract: Alzheimer’s disease (AD) is a progressive neurodegenerative disorder of aging that presents with memory loss, 
disorientation, confusion and a reduction in cognitive ability. Although a deﬁ  nite diagnosis of the disorder can only be made 
post-mortem by histopathological analysis, a number of methods are currently available for the in vivo assessment of AD 
including psycho-metric tests and neuro-imaging. However, these clinical assessments are relatively nonspeciﬁ  c and imag-
ing is very costly. Genetic testing can be performed if familial AD is suspected, although such cases represent a very small 
minority of total AD cases. Apolipoprotein E genotype provides a measure for analysing the risk of developing AD, but 
does not act as an absolute predictive biomarker for AD. Therefore there is a need for an accurate, universal, speciﬁ  c and 
cost-effective biomarker to facilitate not only ante-mortem diagnosis of AD, but also to allow progression of the disease 
and response to therapy to be monitored. This is the ultimate goal that our group is pursuing through the pan-European 
AddNeuroMed project.
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Introduction
Deﬁ  nite diagnosis of Alzheimer’s disease (AD) can only be made upon post-mortem examination of 
brain tissue for evidence of the presence of abnormal protein structures know as neuroﬁ  brillary tangles 
(NFTs) and senile plaques in the hippocampus and cortex of afﬂ  icted individuals (Mattson, 2004; Braak 
and Braak, 1998; Dickson, 1997; Agronin, 2008). However, a number of ante-mortem diagnostic tests 
for AD are becoming available and are being developed with the aim of enabling the trained clinician 
to make a fairly accurate diagnosis of AD in conjunction with information obtained from a comprehen-
sive clinical interview and detailed family history. Such tests are the subject of this review and include 
genetic proﬁ  ling, psycho-metric testing, neuro-imaging and the assessment of protein or metabolic 
products in biological ﬂ  uids. Nevertheless, each test comes with its own set of inherent problems such 
as limited disease speciﬁ  city, high expense or high labour demands (discussed below). Thus, there is a 
need to develop new accurate, inexpensive, easy to perform tests for ‘accessible’ biomarkers of AD 
(unlike NFTs and senile plaques that are inaccessibly located as insoluble aggregates in the brain) to 
enable diagnosis. This need is especially pressing considering that AD is becoming more prevalent as 
life expectancy has increased due to improvements in healthcare and lifestyle. The AddNeuroMed 
project, which our group is intimately involved in aims to address this and represents the largest Euro-
pean effort to identify biomarkers of AD for the use in trials (Lovestone et al. 2007; www.innomed-
addneuromed.com).
AddNeuroMed is a consortium of clinicians and researchers in the ﬁ  eld of AD from across the 
European Union with study sites in Finland, France, Greece, Italy, Poland and the UK. Biological 
samples, including blood, CSF, and urine are being collected at these sites from a large cohort of elderly 
European volunteers with either AD, mild cognitive impairment (MCI: transitional state between 
normal cognition and AD) or normal memory function with the intention of gathering genetic, tran-
scriptomic, proteomic and lipidomic data. The participants have also agreed to neuro-imaging proce-
dures to provide a more in depth assessment of their clinical phenotype. Having begun in 2006, the 
AddNeuroMed study is still in its infancy with longitudinal follow-ups still in progress for the majority 
of participants, which will ultimately enable the assessment of disease progression. In parallel to 
clinical data collection, pre-clinical studies are being conducted using tissue culture, drosophila and 318
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mouse models of AD to screen for potential 
biomarkers and putative signaling pathways 
involved in disease pathogenesis. The AddNeu-
roMed study also serves as a pilot project for the 
Innovative Medicines Initiative, which is a Euro-
pean consortium aimed at improving pharmaceu-
tical research communication and collaboration 
with clinical and research groups across Europe.
Alzheimer’s Disease
AD is a progressive, dementing (from the Latin 
meaning ‘without a mind’), neurodegenerative 
disorder characterised by neuropathological signs 
and identiﬁ  able clinically by an insidious onset 
and deterioration of multiple higher cortical func-
tions resulting in memory loss, disorientation, 
confusion, impaired concentration, alterations of 
language, learning and judgement and a wide-
spread decline in general cognitive function 
(Tanzi and Bertram, 2005; Agronin). The deﬁ  ning 
classical hallmarks of AD are senile plaques and 
NFTs, which are concentrated predominantly in 
the hippocampus and the cortex (Goedert and 
Spillantini, 2006; Hardy, 2006). NFTs are com-
posed of paired helical ﬁ  laments (PHF) of an 
abnormal form of tau, an axonal microtubule 
associated protein (MAP) (Goedert, 1998). Nor-
mally, tau is involved in tubulin polymerization 
and microtubule stabilization and is phosphory-
lated at two to three sites. In AD, tau becomes 
hyper-phosphorylated and consequently dissoci-
ates from microtubules and aggregates into PHFs 
forming NFTs. The reduced binding of phos-
phorylated tau to microtubules results in the 
impairment of vital cellular processes such as 
axonal transport and ultimately culminates in the 
degeneration of affected neurones.
Senile plaques mainly consist of extracellular 
deposits of β-amyloid (Aβ), a peptide produced 
from the proteolytic cleavage of β-amyloid precur-
sor protein (APP). APP is subject to proteolytic 
processing at three sites by the action of α, β and γ 
secretase. Cleavage by β and γ secretase releases 
Aβ, whereas α cleavage is harmless. Intense efforts 
have been directed towards the identiﬁ  cation of α, 
β, and γ secretase. ADAM 10 (Lammich et al. 
1999) and tumor necrosis factor alpha converting 
enzyme (Buxbaum et al. 1998) have been reported 
to mediate α-cleavage of APP. The aspartyl 
protease termed BACE for beta-site APP-cleaving 
enzyme has been demonstrated to mediate 
β cleavage (Vassar et al. 1999) and a multi-protein 
complex consisting of presenilin-1 (PS-1) (Wolfe 
et al. 1999), nicastrin (Li et al. 2003), Aph-1 and 
Pen-2 (Kimberly et al. 2003) is thought to be 
involved in γ cleavage (De, 2003).
There is no question that AD pathology is char-
acterised by the presence of senile plaques, NFTs 
and neuronal loss, but the precise sequence of 
events underlying the pathogenesis of AD remains 
unknown. Probably the most inﬂ  uential theory to 
date has been the amyloid cascade hypothesis 
(Hardy and Higgins, 1992; Hardy, 2006). Accord-
ing to this theory APP synthesis and or processing 
become abnormal due to a combination of genetic 
and environmental factors, which results in the 
formation of senile plaques. The presence of 
plaques subsequently exerts a deleterious effect on 
neuronal survival, leading to the development of 
PHFs and NFTs. Over time the gradual accumula-
tion of these histopathological features is believed 
to cause neuronal death and neurotransmitter 
deﬁ  cits ultimately culminating in dementia.
What is a Biomarker?
A biomarker is deﬁ  ned as a biological parameter 
that can be objectively measured and evaluated as 
an indicator of normal or pathological states or 
pharmacological responses to therapeutic inter-
vention (Atkinson et al. 2001; Lovestone et al. 
2007b; Lovestone, 2006). A biomarker could 
therefore be used for disease diagnosis, as a pre-
dictive marker of disease progression and prog-
nosis or as a tool for staging a condition or 
monitoring a response to targeted treatment. An 
ideal biomarker of AD would therefore encompass 
all of these parameters.
A classical biomarker can be a measure of 
function of a tissue or organ that is detected using 
clinical examination. Examples of such biomark-
ers include measurements of heart rate or changes 
on an electrocardiogram (ECG), temperature 
or blood glucose levels to name but a few. Imag-
ing techniques including X-rays, computed 
tomography (CT), magnetic resonance imaging 
(MRI) or positron emission tomography (PET) 
can also be used to provide a measure of the 
function of a tissue or organ. A molecular bio-
marker can be a genetic trait, a biochemical 
change in protein expression or protein activity 
or an alteration in metabolite levels reﬂ  ecting 
anomalous activity of a certain biochemical 319
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pathway relating to health or indeed disease. 
Tests for biomarkers must demonstrate high 
accuracy, speciﬁ  city and inter-assessment test-
retest reliability if they are to be used with suc-
cess and conﬁ  dence in the clinical setting.
A biomarker, classical or molecular, may also be 
used as a ‘surrogate endpoint’ to substitute for a 
‘clinical endpoint’ (Atkinson et al. 2001; Lovestone 
et al. 2007b; Lovestone, 2006). A ‘clinical endpoint’ 
is an outcome that is measured during a clinical trial. 
A clinical endpoint is a characteristic or variable that 
informs how the patient feels, functions or survives 
providing a measure of morbidity or mortality. 
Therefore, surrogate endpoints can be used to 
evaluate safety and clinical beneﬁ  t and to predict 
the effect of a therapeutic intervention in a shorter 
timeframe. Only a small minority of biomarkers 
become established surrogate endpoints for a par-
ticular disorder. Blood pressure is an example of a 
surrogate endpoint for cardiovascular disease, con-
ﬁ  rmed by the vast amount of epidemiological evi-
dence (Desai et al. 2006).
Genetic Traits and Susceptibility 
Loci Associated with AD
Early onset forms of Familial Alzheimer’s dis-
ease (FAD) typically present before the age of 
65 and as early as 30 years of age and have been 
linked to mutations in APP, PS-1 and PS-2 (Van 
Broeckhoven, 1995). These mutations adversely 
affect APP processing and result in the increased 
production of insoluble Aβ, which is deposited 
in the form of senile plaques. Note PS-2 can 
substitute for PS-1 in the γ secretase complex 
(Steiner et al. 1999). Genetic screening, there-
fore, provides an accurate diagnosis of AD in the 
small number of familial cases (approximately 
2–7% of total cases).
Sporadic AD is a polygenic disease that accounts 
for the majority of AD cases and exhibits a later 
age of onset in comparison to FAD, typically affect-
ing individuals over 65 years of age. The presence 
of the apolipoprotein E (apoE) ε4 allele is a risk 
factor for sporadic AD and increases the chance of 
developing the condition depending on the number 
of copies of this allele an individual harbours 
(Saunders et al. 1993; Yoshizawa et al. 1994). The 
presence of this allele, however, is by no means a 
deﬁ  nitive determinant for the development of AD. 
The apoE genetype alone, therefore, cannot be 
relied upon as a robust predictive diagnostic 
biomarker for AD and is best described as a trait 
as opposed to a state marker of AD.
Assessment of Cognitive Function 
and Memory as a Biomarker of AD
The diagnosis of AD is based on either the National 
Institute of Neurological and Communicative 
Disorders and Stroke—Alzheimer’s Disease and 
Related Disorders Association (NINCDS-ADRDA) 
criteria or on the standards set out in the Diagnos-
tic and Statistical Manual of Mental Disorders 
(DSM—the most up to date being the fourth edition 
test revision). Diagnostic criteria set out in these 
documents include the development of multiple 
cognitive deﬁ  cits manifesting in memory impair-
ment and one or more cognitive disturbances such 
as aphasia, apraxia, agnosia, or disturbances in 
executive functioning and activities of daily living. 
Cognitive deﬁ  cits must exhibit gradual onset, cause 
impairment in social or occupational functioning 
and the presence of other CNS or systemic condi-
tions known to cause dementia must be excluded 
(Thomas, 2008; Agronin, 2008).
Many psycho-metric examinations are available 
as tools for the diagnosis of AD and provide 
an assessment of the key defects of cognitive func-
tion and memory associated with AD set out by the 
DSM and NINCDS-ADRDA working standards. 
These tests also can be used to stage disease pro-
gression allowing the assignment of disease sever-
ity (Rush et al. 2000; Burns et al. 2004; Behl et al. 
2005; Harvan and Cotter, 2006). The advantages 
of such AD tests are that they are inexpensive, do 
not require extensive training to be administered 
and they exhibit good test-retest reliability. Psycho-
metric tests for AD include the mini-mental state 
examination (MMSE), the functional assessment 
staging (FAST), the Alzheimer’s disease assessment 
scale cognitive subscale (ADAS-Cog), the clock 
drawing test, the severe impairment battery (SIB), 
the modified Alzheimer’s disease cooperative 
study—activities of daily living (ADCS-ADL), the 
behavioural rating scale for geriatric patients 
(BGP), the neuropsychiatric inventory (NPI) and 
the clinicians interview-based impression of change 
plus caregiver input (CIBIC-Plus) (Rush et al. 2000; 
Burns et al. 2004; Behl et al. 2005; Harvan and 
Cotter, 2006). These tests involve a series of ques-
tions and tasks for the patient to perform, which the 
interviewer uses to explore registration (the ability 
to recognise and name speciﬁ  c items), encoding 320
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(the processing and combining of new information), 
concentration, memory, language skills and the 
ability to perform daily living tasks. Psycho-metric 
tests are useful for quantifying the degree of cogni-
tive impairment, monitoring disease progression 
and planning adequate care for dementia patients, 
but they do not discriminate AD from other types 
of dementia and the tests are time consuming to 
perform. Moreover, some psycho-metric tests are 
culturally bound and their results may be affected 
by differences in ethnicity and education level lead-
ing to false positive results.
Neuro-imaging as a Biomarker 
of AD
Neuro-imaging techniques can be employed as a 
tool for the diagnosis of AD and using these tech-
niques the presence of vascular damage can also 
be assessed, which is helpful for the discrimination 
between vascular dementia and AD (Agronin, 
2008). The main disadvantage associated with 
neuro-imaging is that it is expensive to perform 
routinely and the scans are distressing for demented 
subjects. Volumetric magnetic resonance imaging 
(vMRI) measures brain volume to provide an indi-
cation of neurodegeneration. At a regional level, a 
reduction in the size of the hippocampus (Kaye 
et al. 1997) and the entorhinal cortex (the input to 
the hippocampus) is apparent in AD (Du et al. 
2003), whilst at the level of the whole brain, a 
reduction in total size accompanied with ventricu-
lar enlargement is evident (Silbert et al. 2003; Fox 
et al. 2000). Magnetic resonance spectroscopy is 
another form of neuro-imaging, which demon-
strates a reduction in the concentration of N-acetyl 
aspartate (a putative neuronal marker) in AD brain 
compared to healthy controls (Meyerhoff et al. 
1994; Frederick et al. 2004).
Functional imaging using [18]ﬂ  uoro-deoxy-
glucose (FDG) PET is another neuro-imaging tool 
available for the assessment of AD. PET provides 
a measure of glucose utilization and such imaging 
reveals a reduction in the metabolic rate of glucose 
in AD in the posterior cingulate, the parietal, the 
temporal and the prefrontal cortices (Alexander 
et al. 2002). PET imaging studies using radio-
ligands such as the Pittsburgh Compound B (PiB) 
that bind Aβ can also be used as a diagnostic mea-
sure for AD (Klunk et al. 2004; Nordberg, 2007) 
and dementia with Lewy bodies (DLB), a disease 
that also features amyloid plaques (Rowe et al. 
2007). Using PiB, or similar amyloid tracers, the 
efﬁ  cacy of anti-amyloid therapies can be monitored 
as a means to reduce amyloid plaque burden and 
perhaps improve cognitive function in vivo. Inter-
estingly, PiB has also been shown to bind to NFTs 
as well as Aβ (Lockhart et al. 2007), thus, in the 
future perhaps enabling clinicians to perform vir-
tual brain biopsies (Agronin, 2008).
Putative Proteinaceous 
and Metabolic Biomarkers of AD
The cerebrospinal ﬂ  uid (CSF) bathes the brain and 
spinal cord and therefore this ﬂ  uid might reﬂ  ect 
pathological changes occurring in the central ner-
vous system (CNS), which relate to neurodegen-
erative disorders. In AD, CSF levels of total tau 
are elevated (Vandermeeren et al. 1993; Blennow 
et al. 1995; Vigo-Pelfrey et al. 1995), although total 
tau is also increased in the CSF in vascular demen-
tia (Andreasen et al. 1998; Nagga et al. 2002) and 
in fronto-temporal dementia (Green et al. 1999). 
Elevated levels of phosphorylated-tau are also 
apparent in AD and in contrast to total tau this 
marker of disease seems to be more speciﬁ  c to AD 
as opposed to other dementias (Vanmechelen et al. 
2000; Itoh et al. 2001; Parnetti et al. 2001; Nagga 
et al. 2002). Reduced levels of Aβ1–42 provide 
another CSF-based biomarker of AD. However, 
Aβ1–42 is also decreased in other dementias and 
is therefore a relatively non-speciﬁ  c marker of AD 
(Nagga et al. 2002; Sjogren et al. 2000). Together 
the combined analysis of CSF total tau and 
Aβ1–42 levels provides the most sensitive and 
speciﬁ  c laboratory-based test for AD and MCI 
(Andreasen et al. 2001; Hulstaert et al. 1999) that 
in conjunction with neuro-imaging and a detailed 
case history could be effectively implemented in 
the clinic and to date provides the gold standard to 
which all other tests for putative molecular 
biomarkers of AD should be compared.
As an alternative to CSF, peripheral blood pro-
vides a readily available plentiful source for labora-
tory testing. The main advantage of using blood 
over CSF as a source for biomarker assessment is 
that it can be easily attained from patients and it 
avoids the need for a lumbar puncture, which is a 
relatively unpleasant invasive procedure and poten-
tially dangerous to perform in demented patients. 
There is a growing body of evidence to suggest that 
blood brain barrier (BBB) integrity is compromised 
in disease states including AD (Hawkins and Davis, 321
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2005; Persidsky et al. 2006) and it is possible that 
central metabolic changes associated with disease 
might also be anomalous in the periphery; as such 
the blood might reﬂ  ect CNS status.
Numerous blood based biomarkers of AD have 
been described in the literature, but as yet none of 
these biomarkers have been sufﬁ  ciently validated 
for routine use in the clinic. We have demonstrated 
that the enzyme glycogen synthase kinase 3 
(GSK3) is up-regulated in circulating peripheral 
white blood cells in AD (Hye et al. 2005). Further-
more, Aβ1–42 is up-regulated in blood plasma in 
individuals with familial mutations in APP, PS-1 
or PS-2 (Scheuner et al. 1996), but Aβ1–42 is not 
elevated in sporadic cases of AD, therefore this 
state biomarker is of limited use in the general 
population. A plethora of other soluble blood-based 
biomarkers of AD have been described and include 
isoprostanes (lipid oxidation products) (Pratico 
et al. 2000), homocysteine (metabolic intermedi-
ate) (Seshadri et al. 2002), p97 (iron transport 
protein) (Feldman et al. 2001), interleukin 1, inter-
leukin 6 (cytokines), α-1 antichymotrypsin (acute 
phase protein/protease inhibitior) (Licastro et al. 
2000), α-2-macroglobulin (acute phase protein/
protease inhibitor) and complement factor H (Hye 
et al. 2006).
Our group has employed image analysis of the 
entire plasma proteome using Two-dimensional-
gel-electrophoresis (Hye et al. 2006). This tech-
nique enables the prediction of AD from control 
patients through pattern recognition with relatively 
high speciﬁ  city and circumvents the issues arising 
from analysis of a single biomarker as a measure 
of disease status; such as poor reliability and 
speciﬁ  city. An ELISA-based approach has also 
recently been used to identify 18 plasma proteins, 
including tumor necrosis factor alpha, epidermal 
growth factor, interleukin 11, interleukin 3 and 
TRAIL-R4 that can be used to accurately distin-
guish AD from control patients. Furthermore, this 
method enables the identiﬁ  cation of patients that 
will progress to develop AD from a state of 
MCI (Ray et al. 2007). Thus, we believe that pro-
teomic or indeed transcriptomic or metabolomic 
approaches should be used in the future to explore 
candidate biomarkers of disease. Such ‘ome’ wide 
proﬁ  ling should provide a more speciﬁ  c and sensi-
tive measure of disease, enabling signature panels 
of changing proteins, transcripts and/or metabolites 
to be identiﬁ  ed and used as biomarkers or even 
clinical endpoints after rigorous validation.
Concluding Remarks
There is a growing requirement for a clinical 
biomarker, or a set of biomarkers, of AD to enable 
accurate ante-mortem diagnosis of sporadic AD 
in a clinical setting without the need for laborious 
and non-speciﬁ  c psycho-metric testing or costly 
neuro-imaging technologies. Ideally a biomarker/
or a panel of biomarkers for AD would allow the 
early prodromal diagnosis of AD and the 
biomarker(s) would correlate with disease pro-
gression and therapy. This would allow for the 
administration of drugs to patients before the 
onset of the core irreversible debilitating symp-
toms of AD, which is when treatment has been 
shown to exert the greatest clinical beneﬁ  t. Fur-
thermore, such a biomarker(s) would enable the 
effectiveness of a given treatment to be readily 
tracked and assessed, which would allow for the 
best possible treatment regimens to be prescribed 
and tailored for an individual patient. Identiﬁ  ca-
tion of such a biomarker or indeed panel of bio-
markers is the main aim of the AddNeuroMed 
project and hopefully this is an achievable goal 
in the not too distant future.
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